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Resumo Este relatório descreve a minha experiência de nove meses como estagiário no
departamento de Investigação, Desenvolvimento e Inovação na Eurotrials
Scientific Consultants, uma empresa dedicada à investigação clínica e
consultoria científica.
A Indústria Farmacêutica tem trabalhado para aumentar a produtividade face
ao aumento dos custos de desenvolvimento de novos fármacos, diminuição
das previsões de receita e aumento do número de compostos a falhar em
estadios tardios do seu desenvolvimento.
Para fazer face a estes problemas, as empresas farmacêuticas estão a
estabelecer parcerias com a academia e com institutos de investigação. Com
este propósito, procurei avaliar quais as áreas de interesse que as Companhias
Farmacêuticas e Companhias de Dispositivos Médicos procuram para
estabelecer parcerias, desenvolvi projectos de investigação básica com a
academia e institutos de investigação e participei em actividades de
transferência de tecnologia. Além disso, tive a oportunidade de participar em
projectos de investigação clínica nomeadamente em estudos da iniciativa do
investigador e também numa formação externa.
Em conclusão, o estágio permitiu-me pôr em prática o conhecimento
adquirido durante este Mestrado, funcionando como uma ponte entre o
mundo académico e o mundo laboral.

Keywords CRO, Pharmaceutical Industry R&D, Medical Devices, Drugs, R&D projects,
Translational Research, Pharmaceutical Medicine
Abstract This report describes my experience of 9 months as an intern in the
department of Research & Development and Innovation at Eurotrials Scientific
Consultants, a company dedicated to clinical research and scientific
consulting.
Pharmaceutical Companies are struggling to deliver improved R&D
productivity in the face of rising development costs, stagnating revenue
forecasts and continued late stage terminations.
In order to increase the number of New Molecular Entities, Pharmaceutical
Companies are establishing partnerships with academia and research
institutes. With this purpose I researched Pharmaceutical and Medical Devices
partnership areas of interest, developed basic research projects with
academia and research institutes and participated in technology transfer
activities. Furthermore, I had the opportunity to participate in clinical research
projects namely investigator driven studies and to be part of an external
formation.
In conclusion, the training allowed me to put in practice what I learnt in the
University, functioning as a bridge between the academic and the working
worlds.
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Introduction
From September 2011 to June 2012, I enrolled in an internship within the scope of the
Master’s degree in Pharmaceutical Biomedicine of University of Aveiro. This internship occurred
at Eurotrials, Scientific Consultants, a Company dedicated to clinical research and scientific
consulting services.  My internship took place at the Research & Development (R&D) and
Innovation department and it was supervised by Dra. Ana Filipa Bernardo.
This report is intended to describe the activities undertaken during this period of nine
months.
The report is organized as follows:
Training objectives.
Overview of the Host Institution – it is described the company Eurotrials and all its
services provided in the context of drug development from bench to bedside. The R&D and
Innovation department is described in more detail, as it was the main work area during this
internship.
State of the Art - it is described the partnerships between Pharmaceutical Companies and
contract  research organizations (CROs) and the paradigm shift in Pharmaceutical Companies that
is taking a more innovative approach through greater collaboration with academia and research
companies.
On the Job Training – it is described the several activities that I had the opportunity to be
involved. Here, I will outline the research made in terms of Pharmaceutical and Medical Devices
Companies main therapeutic areas of interest, describe my involvement in several partnerships
between Eurotrials and academia and research institutes, either in basic or clinical research and
finally, my involvement in an external training session.
Discussion and Conclusion – it has an overview of my internship experience, discussing
what was learned during this period in the R&D and Innovation department and also summarizing
the acknowledgements of the experienced gained during this internship and its importance in the
current environment of pharmaceutical R&D.
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Training Objectives
This internship had three main objectives:
 To characterize and organize the information about potential partners / clients in
order to establish collaborative approaches.
 To be involved in technology transfer assessment from academia resulting in the
translation of research into products.
 To participate in R&D projects through product assessment, regulatory
requirements elicitation, literature review and structuring development plans.
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Overview of the Host Institution
Eurotrials Scientific Consultants is a privately owned company providing consulting and
services for investigation in human health that was founded in 1994 by medical doctors (MD)
members of Academia and Pharmaceutical Industry [1]. Four years later the company decided to
start activities in Brazil and Eurotrials Brazil was formally established in 2001 [2]. Currently it is
also present in Chile and Argentina [2].
Eurotrials is a full service CRO involved in all processes of drug development, from bench
to bedside. The main services provided by Eurotrials are Implementing and Monitoring Clinical
Trials, Regulatory Affairs, Pharmacovigilance, Research and Development Consultancy Services,
Medical Writing, Quality Assurance, Teaching and Training activities, and Data Management and
Statistics (Figure 1) [3].
In January 2001, Eurotrials achieved the ISO 9001 quality certification in Portugal, by the
Lloyd's Register Quality System Assurance (LRQA), with the United Kingdom (UK) Accreditation
Service [5]. Eurotrials has high qualified and motivated research professionals that, together with
the experienced members of the Scientific Committee are deeply integrated into Academia,
Hospitals, Pharmaceutical Industry and other Institutions [3].
Figure 1 – Services provided by Eurotrials throughout the different phases of drug development [4].
Internship Report
4
Eurotrials have worked in all major therapeutic areas, especially cardiovascular, oncology,
metabolic disorders, infectious diseases/AIDS, neurology, psychiatry, pediatrics, women's health,
among others (Figure 2) [4].
My internship in Eurotrials took place in the R&D and Innovation department under the
orientation of Dra. Ana Filipa Bernardo, as previously mentioned. Due to the close collaboration
of this department with other departments I also had the opportunity to participate in an external
training activity promoted by the Teaching and Training (T&T) department. Therefore, I will briefly
present these two departments.
Research & Development and Innovation Department
The R&D and Innovation department is responsible for translational research projects and
proof-of-concept (POC) studies of early development. In this context, the department promotes
collaboration with Academia and Clinical Units to enhance the applicability of the research
conducted at those institutions. The mission of this department is to develop collaborations with
the different stakeholders, Academia representatives, Pharmaceutical Companies, financial
groups and other CROs to develop business connections to be able to develop new research
projects and search for potential sponsorships [3]. In this activity, this department interacts with
Figure 2 – Relative distribution of Eurotrials experience in clinical trials per therapeutic area [4].
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other departments for strategic and regulatory planning of clinical studies, such as the Clinical
Trials and Regulatory Affairs departments.
The main areas of collaboration of this department are: (i) R&D Consulting, (ii) Product
Development Consulting, (iii) Pre-clinical Development, (iv) Clinical Development and (v)
Translational Research [3]. The respective areas of activities are presented as follows [3]:
(i) Research and Development Consulting:
 Analysis of the potential of ideas / projects of R&D
 Definition of a strategic development plan
 Implementation of a development plan
 Regulatory development consulting in accordance with Food and Drug
Administration (FDA) and European Medicines Agency (EMA) guidelines
(ii) Product Development Consulting:
 Technical and scientific analysis of products / projects for R&D
 Defining and implementing a strategic plan for product development, POC
studies execution and translational research.
 Regulatory consulting for development studies to support clinical trials
(Phases I to III), according to FDA and EMA guidelines.
 Technical advice, product development and project tracking - Taylor
made consulting services.
(iii) Pre-clinical Development:
 Consulting in early safety evaluation
 Regulatory consulting for development studies to support clinical trials
(Phases I to III), according to FDA and EMA guidelines.
(iv) Clinical Development:
 Exploratory and/or confirmatory Clinical studies
 Investigator Driven/Investigator-Initiated Studies
(v) Translational Research:
 Clinical validation studies of laboratory research results (translation of
evidence)
 POC studies
 Studies of translational research – evaluation of genetic and functional
biomarkers
 Population-based health studies
 Exploratory studies.
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Teaching and Training Department
The department of T&T is responsible for the development, management and disclosure of
training courses, whether internal or external. Eurotrials conducts many training sessions for
different audiences, such as health professionals, in hospital or industry settings, as well as
students, professors and investigators working in the Academia [3].
It works in collaboration with all other Eurotrials departments helping each sector to
schedule, prepare, conduct, manage and evaluate (when applicable) any training activity that is
being developed.
Figure 3 – Collaborations between R&D and Innovation department and stakeholders [3].
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State of the art – CRO and Pharmaceutical R&D
Contract Research Organizations
The Contract Research Organization (CRO) concept appeared in the global pharmaceutical
and biotechnology markets in order to control in-house R&D costs, expand capacities, and
improve core skills [6]. CRO help and assist Pharmaceutical Companies at every stage of drug
development offering many services that include development of better and advanced products,
manufacturing, conduction of clinical trials, supply of clinical laboratory services to process trial
samples and data management (Figure 4)[7].
Clinical trials are an important and integral part of R&D as far as the Pharmaceutical
Companies are concerned. The efficient and apt handling of the same is required. The complexity
of clinical trials, including the need for further clinical data and for diverse patient populations,
resulted in outsourcing the same to CROs [8]. Clinical trials conducted by CROs are completed
about 30% faster than those conducted in-house by Pharmaceutical Companies [9].
The past few years have challenged CROs to adjust their business models to meet the
changing needs of Pharmaceutical and Biotech Companies. The most successful ones will be those
Figure 4 – Drug Development Outsourcing [4].
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that embrace the three major industry trends: globalization, preferred provider relationships and
investment in new technologies [10].
1. Globalization of Clinical Trials
Globalization of clinical trials provides CROs with the opportunity to run clinical
trials more efficiently and at a lower cost. Pharmaceutical Companies have been including
clinical sites outside of North America and Western Europe for many years where the
main goal is to speed up patient recruitment. Nevertheless, the majority of all clinical
trials are still conducted in the established markets of the United States (US), Canada, and
Western Europe [10].
While driving down overall development cost is an important factor, the largest
benefit by far is the reduction of development time leading to a faster time to market,
which in turn provides an opportunity for a longer post‐approval patent term [10].
Brazil, Russia, India and China, named as BRIC Countries are promising locations
for future clinical studies, and pharmaceutical companies are currently expanding their
drug discovery, development and commercial programs [10]. This represents a shift in
global economic expansion away from traditional, developed countries to countries with
newly advancing economies.
2. Preferred provider relationships
Preferred provider relationships between Pharmaceutical Industry and CROs are
not new. In fact these agreements are really important once it can provide large
customers with dedicated teams and significant volume-based pricing advantages to
conduct late-phase clinical programs.
The CRO/sponsor relationship grew up in times of high profitability and therefore
there really was not very much of a focus on operational efficiency. Now, with the
average cost to bring a drug to market well over one billion dollars, efficiency and cost
savings are the real drivers of partnership/alliance relationships. Longer-term
partnerships, accelerates start-up times and minimizes administrative, training and set-up
costs. Long-term partnerships afford both the CRO and the sponsor the opportunity to
develop and track metrics around key performance indicators over a longer period of
time, more accurately assessing the true value of the partnership [10].
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Sponsors are leveraging CROs broad expertise and capabilities and CROs are
taking on more comprehensive pieces of the development process, along with more
responsibility. Partnerships are being structured around delivering value to sponsors as
opposed to just a task [10].
Strategic partnerships play a prominent role in helping Pharmaceutical Companies
more effectively meet development and commercialization goals. Critical elements of
these relationships include the ability to create value for the sponsor and deliver benefits,
such as faster cycle times. To be successful, partnerships must have well-developed
governance constructs, open collaboration, a deep level of information exchange, and an
outcomes-based approach, focused on sharing the risks and rewards [10].
3. New technologies
The adoption of the latest technology will improve a CROs work product and
make it more appealing to potential customers. Sponsors, investors, and regulatory
agencies constantly seek immediate information, an objective that extends to all facets of
clinical development. In addition, study sponsors now demand constant global access to
site status and patient enrollment information. An example of services developed to
meet these needs is the use of electronic data capture and internet-based clinical trial
management systems that have made data available in real-time anywhere in the world
and only the CROs able to provide it will be successful moving forward [10].
Thanks to the adjustments made to their business model, CROs are growing and provide
substantial global capacity to drug developers and have become a critical contributor to clinical
trial activity. Usage of CROs will rise by 9.9% annually through 2013 with the greatest growth in
Phase IIIb and IV testing at 13.8% per year. The total CRO market size is estimated at $20 billion
(bn) dollars in 2008 and expected to grow at an annual rate of 8.5% to reach $35bn through 2015
(Figure 5)[11]. The market is highly fragmented and the number of CROs worldwide has reached
over 1,100 despite continued consolidation [9].
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In conclusion, what started out as a cottage industry has become a sector worth $15 bn in
2007, and a highly consolidated one, with the top 10 companies controlling 56% of the market,
and employing tens of thousands of workers across the world [12]. CROs have developed a set of
expertise and proprietary knowledge and technology to rival any pharmaceutical company. Their
basis in profitability problems of Pharmaceutical Industry means that they are not going to be
facing any shortage of clients in coming years, but they also now represent a key part of the
division of labor in healthcare, that does not seem like going anywhere.
Figure 5 – Estimated global CRO market growth (2008-2013) in billion US dollars [4].
CAGR - Compounded Annual Growth Rate.
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Pharmaceutical Industry R&D
Up until about 20 years ago, the biomedical community did a great job of coming up with
breakthrough discoveries and translating them into commercial products. The translational
research that was carried out by the Pharmaceutical Industry was frequently quite disruptive of
established practices and standards of care [13]. The development of a new drug used to cost
$200 million and took seven years to reach the market, which led the Pharmaceutical Industry to
reach its peak of profitability in the 1990s with heavily marketed drugs for common afflictions,
like AstraZeneca’s Nexium for heartburn and Pfizer’s Lipitor for high cholesterol.
Pharmaceutical Industry have improved and extended the lives of millions of people.
Nonetheless, the many advances over the past couple of decades have not come without
controversy, much of it centering on the massive profits the industry makes on blockbuster drugs
[14]. A blockbuster is a drug that, once approved, will generate $500 million in sales annually
(some have raised this revenue bar to $1 billion or more). Drugs that are able to achieve this
threshold are true wonders for their creators, because this income level of means wonderful
profits, even after manufacturing costs, regulatory costs and distribution costs are taken into
account [15]. This is why the traditional innovation model which prevailed for many years in the
Pharmaceutical Industry was the “blockbuster” model.
The “blockbuster” model
The problem with focusing on blockbusters is that every pharmaceutical company was
following the same strategy, and now most the medicines for “simpler” diseases have already
been discovered. Worse, the search for blockbusters diverted companies from addressing unmet
medical needs of smaller patient populations on one hand, and led them into launching numerous
me-too drugs on the other hand [15]. Historically, pharmaceutical companies have faced
competition at an ever-increasing pace because markets have sustained multiple products with
little or no differentiation. The average time a medicine is the only drug available in its
therapeutic class has declined dramatically – from more than 10 years in the 1970s to less than 2
years by 1998 [16].
The “blockbuster model” is a vertically integrated approach to innovation, where all the
key activities are performed inside the four walls of the pharmaceutical company, hence a closed
model. As a closed model, it entails a high fixed cost for the firm due to the high attrition rate for
compounds from initial exploration through to the market. This model has made Pharmaceutical
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Industry leaders grew increasingly uncomfortable with the risk and unpredictability inherent to
drug R&D. They imported and adopted what turned out to be inadequate tools to manage risk
and reduce uncertainty. The result was to transform drug R&D from a creativity-led enterprise to
a process-led endeavor [13].
R&D Productivity
The impact on innovation has been severe. Pharmaceutical Companies are struggling to
deliver improved R&D returns in the face of rising development costs, stagnating revenue
forecasts and continued late stage terminations. Currently, bringing one new drug to market takes
roughly 14 years, at a cost of about $1.3 bn. For every drug that makes it to market, more than 50
other research programs fail. After all that, only two of every 10 newly approved drugs will be
profitable. Those profits must fund not only all the research programs that failed, but also all the
drugs that are launched but lose money [14]. Due to this, Forbes magazine recently highlighted
the fact that new drugs at some pharmaceutical companies could cost at least $4 bn, and it can be
as much as $11 bn. This numbers are obtained by dividing each drug company’s R&D budget by
the average number of drugs approved [17].
Company Number of
drugs approved
R&D Spending per
Drug ($Mil)
Total R&D Spending 1997-
2011 ($Mil)
AstraZeneca 5 11,790.93 58,955
GlaxoSmithKline 10 8,170.81 81,708
Sanofi 8 7,909.26 63,274
Roche Holding AG 11 7,803.77 85,841
Pfizer Inc. 14 7,727.03 108,178
Johnson & Johnson 15 5,885.65 88,285
Eli Lilly & Co. 11 4,577.04 50,347
Abbott Laboratories 8 4,496.21 35,970
Merck & Co Inc 16 4,209.99 67,360
Bristol-Myers Squibb Co 11 4,152.26 45,675
Novartis AG 21 3,983.13 83,646
Amgen Inc. 9 3,692.14 33,229
Table 1 – Pharmaceutical companies R&D spending (in Million US dollars, $Mil) and number of new drugs
approved between 1997 and 2011 [17].
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Despite tremendous efforts, pharmaceutical innovations at the patient level are becoming
rare events. To shed light on the R&D productivity problem, a recent report evaluated 450 new
drugs approved by the FDA between 1996 and 2010. The 15-year study period fell into two
segments: an “Era of Abundance” (1996-2004) characterized by robust approvals and high return
on capital, and an “Era of Scarcity” (2005-2010) characterized by fewer approvals, weaker sales,
and low return on capital. The landmark that separates the two periods is the Vioxx withdrawal of
late 2004 [18]. In the “Era of Abundance”, the FDA approved an average of 36 New Molecular
Entities (NME) but then, due to a higher scrutiny from drug regulators, we have seen a slowdown
in the “Era of Scarcity” to just 22 NME, representing a 40 percent descent in drug approvals
(Figure 6) [18]. However, last year, the FDA stamped approvals on 35 new medicines, including 2
new hepatitis C drugs, 11 treatments for rare diseases and the first new medicine for lupus since
1955 [19]. Whether this is the turning point or a mere coincidence will only be clarified over the
next few years.
Yet one could argue that the sales of new drugs are not supporting the massive
investments in R&D that have been made over the past decade. Besides the lower number of
NME, the “Era of Scarcity” is also associated with less value for each new drug generated. The
average fifth-year sales for an individual drug fell from $515 million in the “Era of Abundance” to
$430 million in the “Era of Scarcity”, a decline of more than 15 percent – and one that is all the
more noteworthy because it comes after a decade when revenues realized by new launches
Figure 6 – The decline of R&D Productivity over time [18].
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steadily increased, driven by the globalization of the industry, a receptive pricing environment,
and increasingly sophisticated sales techniques [18]. If one relates the impact of a decrease in the
number of NME with the fact that each NME entails a smaller average sales the result is a 50
percent drop in value - from $18.3 bn generated by the average new drug cohort in the first
period, to $9.4 bn during the second. This significant decrease is driven at least in part by the
decline in the number of blockbusters: 12 per year in the “Era of Abundance”, six in the “Era of
Scarcity”. Finally, measuring R&D productivity is notoriously hard given the numerous inputs and
outputs and caveats to apply, nevertheless combining the previously mentioned facts with an
ever increasing R&D spending, the result is a decline by more than 70 percent between the two
periods (Figure 7) [18]. In the Era of Abundance, Pharmaceutical Companies produced an average
of $275 million in fifth-year sales for every $1 bn they spent on R&D. During the Era of Scarcity,
the equivalent figure was $75 million. The change is dramatic - fewer, less valuable drugs that cost
a lot more - and it points to a deeper concern: the economics of spending $1 bn on R&D and
generating $75 million in fifth-year sales are not sustainable [18].
Global Spending on Medicines
Annual global spending on medicines will grow from $950 bn now to $1.2 trillion in 2016,
as the pharmaceutical markets from emerging countries, biologics and generics contribute more
to spending. In the developed markets, including the United States, Europe and Japan, spending
will decline to 57%. The developed markets are expected to grow slowly due to patent expiries
and the sustained impact of the global economic crisis felt in these countries since 2008. In the
US, spending growth will recover, but remain at historically low levels. In Europe, growth is
Figure 7 – Industry R&D productivity has dropped more than 70% [18].
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expected to be in the -1% to 2% range through 2016, compared to 3.8% for 2007-2011, as
national debt incurred due to the global economic crisis is anticipated to be addressed through
austerity programs and healthcare cost containment. The Japanese market for pharmaceuticals
will increase slightly over the next five years with growth forecast between 1-4% and punctuated
by biennial price cuts [20].
On the other hand, pharmaceutical markets from emerging countries will reach 30% of
global spending by 2016, as population and economic growth contribute to dramatically higher
use of medicines in these markets. The emerging countries will double their spending on
pharmaceuticals over the next five years, as annual growth is forecast to increase from $24Bn in
2012, to $35-45Bn in 2016. Spending on medicines in these emerging markets will increase by
$150-165Bn, driven by rising incomes and macroeconomic expansion, and increasing access to
medicines supported through a range of government policies and programs [20].
An accelerated shift to the use of generic medicines is expected. Global spending on
brand meds is projected to increase from $596 bn last year to $615 to 645 bn in 2016, mostly in
developed markets. By contrast, global generic spending is expected to increase from $242 billion
to $400 bn to $430 bn by 2016, of which $224 bn to $244 bn of that increase is forecast to come
from spending on lower-cost generics in emerging markets (Figure 8) [20].
Figure 8 – Estimated global spending on medicines (2011/2016) [20].
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In these markets, 65% of about $360 million in sales will be from generics. In the
developed world, only 18% of $675 million in sales will be from generics. That leaves branded
drugs with just $680 million in sales, a bit more than half the market, with cheaper generics taking
the rest [21].
Pharmaceutical Business Model Disruption
Global drug makers face an extremely turbulent decade from which only highly innovative
medicine makers and large-volume generics makers will emerge, with players who try to occupy
the middle ground largely disappearing [22].
Pharmaceutical companies that manage to deliver "true innovation", with the kind of
products that not only satisfy regulators but deliver outcomes data that impress budget-minded
payers, will be able to withstand these difficult times. Generics makers can as well, although their
numbers will likely be reduced through consolidation as they seek to benefit from economies of
scale. But the companies that only turn out “me-too drugs”, with “limited differentiation”, will not
get payers' money and will not survive [23].
However, the R&D returns for the pharmaceuticals and biotech sector have reached
critically low levels where the Pharmaceutical Industry as a whole is hardly recouping the cost of
capital. That coincides with looming expirations on key drug patents, tightening budgetary
constraints by governments, and increasingly stringent regulatory hurdles for new products [22].
Back in 1990, the top 50 Pharmaceutical Companies could boast a 17% return on investment (ROI)
on their research budgets. Last year that dropped to only 10%. And if some of the developers
were forced to break out their ROI, they would be in the red [22].
Spending billions a year delivered only a meager trickle of new drug approvals, leaving the
chief executives, pressured from shareholders for greater transparency on research, to pledge
bold new approaches that would both scale back the amount they were spending and boost their
success rate [22].
Companies need to abandon their “broken innovation model”. The old model of the large,
vertically integrated drug company that did everything from drug discovery to development to
bringing the product to market, yet was shrouded in corporate secrecy, is slowly fading [14].
There are signs that pharmaceutical companies are following through on their pledge to
break down some of the high walls built around R&D as they go out and work more with
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academic investigators, biotech companies and other pharmaceutical outfits in the much
heralded “open innovation” model that is being fostered worldwide. That new approach to
discovery and development is crucial to Pharmaceutical Industry ability to change the equation on
its return on investment [24].
Open Innovation
When Henry Chesbrough created the term “open innovation”, he meant that knowledge
is widely distributed in the modern world, and that companies should not just rely on internal
sources of innovation; they should also use external ideas. The trend towards open innovation is
particularly marked in the life sciences industry, largely because it has been struggling to develop
good new medicines by itself. With little to show for all the money they had invested and patent
expiries set to erode a substantial amount of their revenues, many companies realized they
needed to look beyond their own walls [25].
Open innovation can actually improve these economics, and in doing so, open up markets
that are not economically attractive in the closed model. Taking a more innovative approach
through greater collaboration has already proved successful (Figure 9). The walls of secrecy are
coming down in some cases and there are increasing numbers of players within the industry
Figure 9 – The past and the future of pharmaceutical R&D innovation models [25].
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forming alliances and joint ventures [26].
Pharmaceutical Companies actively scan the external environment, from universities and
research institutes early on, to startups and specialty Pharmaceutical Companies later on, for
possible drug candidates that fit their business model. In doing this, they do not have to pay the
full cost of development from scratch. They only pay for the costs past a certain stage. In addition,
instead of securing all rights to the drugs for all disease indications, they can focus on the rights
for diseases they serve in their markets, and license to others the rights for alternative markets.
This enables them to cut better deals at lower costs for themselves [15].
The scope of the partnerships is wide and the sheer number of partnerships at
Pharmaceutical Companies is staggering. Merck, for example, has listed on its website more than
75 partnerships with Pharmaceutical Companies and academic institutions, and these are only
the publicly announced deals, with scores of others are yet unannounced. Lilly has over 100
active partnerships, according to the Company. GlaxoSmithKline has a whole unit, the Academic
Discovery Performance Unit, whose whole focus is to partner with academic researchers to bring
their discoveries to market. Based on publicly available data including company websites, it seem
like each Pharmaceutical Company is now managing over 100 R&D and commercial partnerships
[27].
In addition to the focus on possible drug candidates, the pharmaceutical R&D sector can
do more to work together, for example sharing knowledge on the science behind failed molecules
and studies will help improve success rates, and ultimately bring down the cost to develop new
medicines. National Health Institute (NIH) has done just that with its new translational medicine
initiative, outlining a new partnership between the National Center for Advancing Translational
Sciences (NCATS) and Eli Lilly, Pfizer and AstraZeneca that will provide investigators access to
failed drugs to see if they can be repurposed for new uses. The purpose is clear, Pharmaceutical
Companies will offer up their data and investigators will have a chance to explore new uses, with
a set of deal templates in place to help speed the process on 20 programs. In drug research, it is
not at all unusual to see a drug intended for one disease work in another [28].
Finally, open innovation in non-competitive areas of the R&D operation might also be
truly important in order to boost the quality of clinical trials and speed up the typically slow pace
of drug development. Ten of the world's largest Pharmaceutical Companies have joined forces to
form a nonprofit that aims to address the types of pre-competitive projects that could help all of
the Pharmaceutical Companies reduce some of the nettlesome issues that contribute to poor
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returns on R&D investments. The nonprofit's supporters have agreed to fund 5 initial projects that
include:  (i) development of a shared user interface for investigator site portals, (ii) mutual
recognition of study site qualification and training, (iii) development of risk-based site monitoring
approach and standards, (iv) development of clinical data standards, and (v) establishment of a
comparator drug supply model. The results of these projects may contribute to achieve better
efficiency in clinical trials and thereby reduce its costs [29].
Rationale for the creation of the R&D and
Innovation Department
All the above mentioned factors that culminated in the emergence of a new innovation
policy, open innovation, led to the creation of this department. With a continuous growing
number of Pharmaceutical Companies turning their R&D interests into Academia partnerships this
department aims to be the bridge between the Pharmaceutical and/or Medical Devices
Companies and the Portuguese  research Institutions and theirs basic and clinical researchers.
In the meanwhile, government initiatives have strengthened the commitment in the
creation of this department. Government has targeted entrepreneurship and innovation as
priorities and as such, a Strategic Plan on Entrepreneurship and Innovation was approved in 2011
to improve Portugal’s overall competitiveness. Actions include the diffusion of an
entrepreneurship culture and related skills and competences, the promotion of domestic and
international knowledge flows, and the development of dedicated financial instruments [30].
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On the Job Training
During my internship in the R&D and Innovation department in Eurotrials, I had the
opportunity to be involved in several activities. The main objective of this department, aligned
with the major events going on in Pharmaceutical and Medical Devices Companies R&D strategy,
is to bond alliances and forge partnerships between these companies and Portuguese universities,
research institutes and start-up companies. Thereby, developing translational research projects,
POC studies of early development and structure an R&D strategy to enhance the applicability of
the research conducted at the universities and research institutes.
Creating Partnerships
In order to be able to make the bridge between Pharmaceutical Companies and
Portuguese universities, research institutes and startup companies, it is of utmost importance to
map the expression of interest by the pharmaceutical industry in partnerships with scientific
institutions and the areas of potential collaboration, in terms of therapeutic areas and the
purpose for these partnerships. Therefore, my first assignment was to screen Pharmaceutical
Companies’ websites for partnership interests.
In this survey it was found that most enterprises have on their websites an area devoted
to the development of new partnerships. This was not in some way surprising because it reflects
the biopharmaceutical framework of change, including the constraining factors in the
development of new medicines discussed on the previous chapter. However, it is a new and
growing reality. Merck, for example, has a strong motto “Combining our strengths, Sharing our
Successes” and a very clear idea of what they want to do: “Merck's mission is to turn
breakthrough science into novel medicines and expand access to our products in order to improve
patients' lives. To support these objectives, Merck actively seeks strategic partnerships to
complement and enhance our original research and product portfolio” [31]. This is just an
example of how pharmaceutical interests have a growing interest in R&D outside their companies.
In order to complete this assignment, 20 Pharmaceutical Companies’ websites were
screened and the methodology used to track these companies was the list of associates of the
Portuguese Association of Pharmaceutical Industry (APIFARMA)
(www.apifarma.pt/apifarma/Paginas/Associados.aspx). The Pharmaceutical Companies selected
were the so-called “Big Pharma”, that is, Pharmaceutical Companies with the highest turnover, as
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well as the highest spenders in R&D. This selection was not based on a strict criterion. It was a
selection strategy based solely on the assumption that this type of companies, given the size of its
revenues, would have a greater ability to promote partnerships. The result then reflects only the
analysis of this segment of companies and we believe that is representative since 20 out of 50
companies were analysed. Among the screened websites, while some of them had very detailed
information regarding what they want to pursue in a partnership, with a “Partnering Brochure”,
others had the information just on their website.
With the information retrieved from the websites and/or partnering brochures, it was
possible to characterize Pharmaceutical Companies’ main areas of interest. Pharmaceutical
Companies’ interests can be diverse but it is possible to highlight the main purposes that drive
them into establishing new partnerships (Figure 10). The top 4 therapeutic areas are: (i) novel
targets, (ii) biologic medicines, (iii) personalized medicine and (iv) drug discovery and preclinical
development.
(i) The main drive for Pharmaceutical Companies to look for outside of their walls is for
novel targets (Figure 10). At a time that R&D spending on “me-too drugs” is no longer
acceptable, the search for novel targets is of utmost importance and the best place to
search for these is on academia and research institutes, places of excellence for basic
science research.
(ii) Biologics significance is growing and they now seen as important as small molecules.
Biologics have been heralded as the next great revenue opportunity for
pharmaceutical R&D [32]. Indeed, they have higher probabilities of success (POS) than
small molecules (an analysis of industry’s phase successes and failures for innovative
drugs between 2006 and 2010 indicated a 12% POS from Phase I to launch for biologics
and a 7% POS for small-molecule drugs), as well as higher average peak sales and a
slower decay of sales following loss of exclusivity than small molecules [33].
(iii) Pharmaceutical Companies interests in biomarkers and molecular diagnostics is tightly
connected with the dawn of personalized medicine. The success of personalized
medicine depends on having accurate diagnostic tests, through biomarkers, that
identify patients who can benefit from targeted therapies.
(iv) Finally, it is possible to observe that there is a growing interest in establishing
partnerships early in the process of drug discovery and preclinical development.
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Additionally, research on the therapeutic areas of partnership interest was also
investigated. It is not a surprise that the therapeutic areas of greater interest to Pharmaceutical
Companies are also those with unmet medical needs (Figure 11).
These therapeutic areas correspond to chronic diseases, with a higher prevalence in
developed countries, thus the type of diseases that guarantee a higher ROI to these companies.
The top 5 therapeutic areas are: (i) Immunology, (ii) Oncology, (iii) Neurosciences, (iv) Metabolic
Pathways and (v) Cardiovascular Diseases. In conclusion, this analysis has not deviated much from
the strategic focus of the industry pipeline.
Figure 10 – Number of Pharmaceutical Companies that report a specific area of purpose for the
establishment of partnership. Data referred to 20 companies analyzed.
Figure 11 – Number of Pharmaceutical Companies that report specific therapeutic areas of interest to the
establishment of partnerships. Data referred to 20 companies analyzed.
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In the analysis of the information of the Pharmaceutical Companies websites, it was also
identified that the collaboration with academia is usually promoted in two ways. One, more
general, where there is information regarding the interests of the company; in this case it varies
considerably among the several websites. And one very specific, named call, when a
pharmaceutical company wants a very specific collaboration in a given area; this last type is
present in lower numbers.
In terms of possible models of partnerships established between these Pharmaceutical
Companies and academia/research institutes it was identified that they are usually presented in
two models. The first model stands when academia/research institutes have a defined idea
and/or project and this is aligned with the interests of the Pharmaceutical Company. The second
model is when a Pharmaceutical Company acknowledges a given university or research institute
for its know-how and technical potential and wants to partner with them in order to develop joint
projects as a service delivery.
This strategy was also applied to Medical Devices Companies’ websites. Medical devices
have an enormous diversity of assets and provide an invaluable support to the treatment of
several diseases. Unlike what happens in pharmaceutical industry, where a small number of
companies comprise most of the assets, medical devices industry is widespread through a far
more impressive number of companies. This can be explained by the different processes of
development and regulatory environment of both products.
As opposed to the Pharmaceutical Companies’ websites research, where the intention
was to fully characterize these companies’ interests, the medical devices research had as a
primary goal to identify these companies and its therapeutic areas, to establish a communication
plan in order to present Eurotrials services, in particular, at regulatory level. Due to this, this
survey was performed without following a specific categorization.
More than 70 Medical Devices Companies’ websites were screened and the methodology
used to track these companies was the analysis of Portuguese and European medical devices
sites, Apormed (www.apormed.pt) and Eucomed (www.eucomed.be), respectively. As expected,
numerous therapeutic areas of interest were found and the ones where these companies showed
most interest are (i) vascular, (ii) respiratory, (iii) orthopaedics and (iv) urology (Figure 12). In
figure 13, particular interests of these Companies were screened and are represented in more
detail.
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Additionally, 36 Portuguese startup health related companies were screened and
characterized regarding their area of activity. These companies were identified through Health
Cluster Portugal associates listed in its website (www.healthportugal.com) and through the search
in the ever growing number of business incubators. This survey was conducted further to the
survey of Pharmaceutical Companies’ interests with the purpose of mapping these startup
companies with the purpose of evaluating the possibility of establishing a match between these
companies with a Pharmaceutical Company interest.
Figure 12 – Number of Medical Devices Companies that report specific therapeutic areas of interest to the
establishment of partnerships.
Figure 13 – Greater detail on more particular interests of Medical Devices Companies to the establishment
of partnerships.
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Leverage Partnerships
The R&D department gains special relevance with the concept of translational medicine.
This concept is defined as the efficient and effective translation of basic scientific findings relevant
to human disease into knowledge that benefits patients [34]. It aims to accelerate the rational
transfer of new insights and knowledge into clinical practice, improving patients’ outcomes and
Public Health [35]. This is a multidisciplinary effort, involving coordinated efforts between
Academia, Regulatory Authorities and Industry [34].
Eurotrials sees great potential in translational medicine as a pathway for the development
of novel and effective treatments and through client characterization previously done, the goal is
to establish partnerships between these and Academia, as well as basic research institutes and
startup companies, with the objective of accelerating knowledge and technology transfer, from
basic to applied science. The efforts of Eurotrials towards translational medicine aim to promote
the clinical applicability of basic science and knowledge, as well as to streamline clinical research
and development.
Among academic scientists there is frequently a misunderstanding between product and
technology and in some of these projects this misperception was present. In order to shed light in
this subject it was elaborated a “R&D Application Form”. This tool is pretended to facilitate the
identification of the product / technology and to be used as a technology transfer tool. This “R&D
Application Form” needed to fully characterize the product / technology; therefore it must have
multiple fields:
 Description - provide a brief description regarding the background of the product
/ technology.
 Define the product / technology - Technology name and one very brief sentence
describing what the product / technology does.
 Potential Applications - Briefly state in which industries may your product /
technology be useful.
 Relevance of the product / technology - Explain which is the problem that the
product / technology is addressing.
 Innovative aspects and main advantages - What makes the technology unique.
List the advantages.
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 Potential disadvantages - Explain the possible disadvantages of the product /
technology.
 Stage of development - Describe the past and current development phase (In
vitro POC, in-vivo POC, clinical evidences).
 Intellectual Properties Rights - Patent application status (not submitted,
submitted under evaluation, granted). Has the information been disclosed prior
to patent submission?
Within this activity, numerous meetings were done and some projects were initiated.
Hereinafter, it will be presented some of the projects I was enrolled with.
Academic Partnerships
Eurotrials has already some history regarding academic partnerships. At the present,
there are two academic partnerships established, one with a renowned university and the other is
a R&D platform. This R&D platform is an oncology R&D platform, linking multidisciplinary partners
with complementary and synergistic skills, between CRO (Eurotrials), one basic research institute
and two healthcare units. The goal of the platform is to assume a framework, similar to that of an
enterprise, which values and enhances the skills of the several partners in clinical and
translational research. This innovative collaborative approach main purpose is to boost clinical
and translational research, create value from scientific results and enhance product development
through POC studies. The ultimate objective is to establish partnerships with Pharmaceutical
Companies.
As Pharmaceutical Companies are putting more and more efforts into R&D partnerships
and Portuguese academia and research institutes are on the same struggle as all academia and
research institutes across the world, projects presented to these companies need to be well
structured and clearly presenting the novelty and the advantages of their projects. My
participation in this project was to study two projects of this research institute, review the
literature and to emphasize the advantages and the uniqueness within these projects.
In regard to the collaboration with the university, the partnership was established in 2010
towards achieving the objectives of (i) value creation (transposition of science and knowledge to
the market), (ii) development of new and innovative solutions in healthcare, and (iii) partnering in
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a collaborative investigation (a partnership between businesses, healthcare facilities and research
institutes).
This partnership involved two types of projects:
I. The project is still in its early stages, the result of basic science research and there
is no clear pathway and/or a potential application in mind. In this case, the “R&D
Application Form” is delivered to the investigator in order for him to fill out the
form, one for each potential application. After receiving all forms, R&D and
Innovation personnel department will evaluate and organize a market research
for each potential application in terms of competitors, profitability, regulatory
requirements and surveying of potential partners. After all of this, it is chosen the
potential application with the best probability of success.
II. The project has a well-defined application and the main goal of the partnership
was to structure a development plan, a POC, in order to fully characterize the
product/technology, confirm its relevance and innovative aspects with the final
purpose being the confirmation of its potential application(s).
It was given to me the opportunity of working with two University Units, the first being a
top national research institute and the second a hospital.
Project I
When I first joined this project, a first meeting had already happened and in that meeting,
one unit of that research institute presented their current projects and the available results. The
output of this meeting was a report that presented research activities performed by this unit and
the collaboration opportunities between Eurotrials and this institute within these projects. The
idea was to assess, evaluate the applicability and to elaborate product development plans.
I attended a second meeting aimed to review the report of Eurotrials. All projects were
discussed in order to further clarify and align technology concepts. This process becomes essential
because it allows the speeding up of the process and culminates in better characterization of the
opportunities and also defines the following steps.
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As explained above, the R&D application form was then sent to the investigators, one
form for each project. At the moment of reception of the form, my task was to evaluate each
potential application regarding the aforementioned terms. To achieve this, I performed a review
of the literature so that I was able to acknowledge the project and perform a correct and accurate
evaluation. After having more insights on the project, I evaluated its novelty and its advantages
regarding the state of the art.
Following this research, a final meeting occurred to present the output of the research
and to inform the investigator of the paths that he can pursue along with the design of the
roadmap for product development.
Project II
Another study already underway that I had the opportunity to participate was in a clinical
development plan for an advanced therapy product. As opposed to project I, this project had a
well-defined application and the main goal of this partnership was to develop a POC study to
confirm its potential application.
At the moment that I joined this project, Dra. Filipa Bernardo had prepared an in vitro POC
and a meeting was scheduled to present and to debate this in vitro POC. The in vitro POC proposal
aims to demonstrate the feasibility of the project and serve as a basis for further studies in animal
models and in humans [36].  To join this project, there was the need for me to study the
applicable legislation and a literature update on the state of the art, especially on the
methodology.
Advanced Therapy Medicinal Products (ATMP) are medicinal products which are
prepared industrially or manufactured by a method involving an industrial process [25]. ATMP fall
into three categories: Gene Therapies, Somatic Cell Therapies and Tissue Engineered Products.
Given the novelty, complexity and technical specificity of advanced therapy medicinal products,
specially tailored and harmonized rules are needed to guarantee a high level of health protection,
as well as to harmonize and facilitate market access, foster competitiveness and provide legal
certainty. Among them, the following documents specific to advanced therapy products can be
found:
 European Commission (EC) Law :Regulation (EC) No 1394/2007 of 13 November
2007 [37], Regulation (EC) No 668/2009 of July 2009 [38].
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 EMA guidelines: Guideline on safety and efficacy follow-up [39], Guideline on the
minimum quality and non-clinical data for certification of advanced therapy medicinal
products [40].
The regulatory framework for ATMP is established the by Regulation on advanced
therapies [37], planned to ensure the free movement of advanced therapy products in Europe, to
facilitate access to the EU market and to promote the competitiveness of European companies in
the field, while guaranteeing the highest level of health protection for patients [34]. The main
points of the Regulation include a centralized marketing authorization procedure, to benefit from
the pooling of expertise at European level and direct access to the EU market. Following the
European regulation on ATMP, a consolidated regulatory framework for these innovative
medicines has recently been established. Central to this framework is the Committee for
Advanced Therapies (CAT) at the EMA, comprising a multidisciplinary scientific expert committee,
representing all EU member states and European Free Trade Association countries, as well as
patient and medical associations.  In order to monitor scientific developments the legislation is
constantly being reviewed to make safe, novel treatments available to patients as soon as
possible [35].
This new Regulation also marks the recognition that a number of advanced therapy
products actually combine biological materials, such as tissues or cells, and chemical structures
such as metal implants or polymer scaffolds. These combination products lie at the border of the
traditional pharmaceutical area and other fields. They, therefore, cannot be regulated as
“conventional” drugs and need adapted requirements. In addition, a significant share of economic
operators involved in this field are not large pharmaceutical companies, but rather small and
medium-sized enterprises (SMEs) or hospitals [37].
A month later, a second meeting was arranged to discuss some changes made to the
initial in vitro POC, this time with the principal investigator of the study. This meeting resulted in
the development of the final in vitro POC version, in which I was able to participate. The final step
was to prepare an outline of the project and the budget estimate. This outline in now finalized
and ready to be presented to Pharmaceutical Companies.
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Investigator-Driven Studies
Investigator-driven studies (IDS) are clinical trials that are initiated by academic
researchers and whose main goal is to acquire scientific knowledge and evidence to improve
patient outcomes. These studies target potential diagnostic and therapeutic innovations that do
not attract or may possibly be in contradiction with commercial interest. Typical examples are
POC studies, studies on orphan diseases, comparison of diagnostic or therapeutic interventions,
surgical therapies or novel indications for registered drugs. IDS thus have a much broader scope
and potential impact than industry-driven clinical trials. IDS form a key part of patient-oriented
clinical research, and create the basis for continually improving patient care [41].
Complying with the submission regulations can be daunting and an overwhelming burden
to faculty researchers who are rarely familiar with their obligations as sponsors of a clinical trial
application (CTA). Having in mind that clinical trials, in which is included CTA, is the core business
of the company, Eurotrials can be a valuable partner to assist these academic researchers in their
IDS application to the Competent Authorities.
During my internship in Eurotrials I had the opportunity to participate in two IDS, the first
being an interventional study and the second a working package for observational studies
submission.
IDS Project I
The first was an interventional randomized double-blind placebo-controlled study on an
unmet medical need. The purpose of the study was to evaluate the efficacy of the study drug,
already on the market, for a new indication, repurposing the drug. I had the opportunity to
participate in this project since its inception, therefore I participated in the submission procedures
of this clinical trial.
Clinical trial definition, in Article 2 (c) of Directive 2001/20/EC [42], is “any investigation in
human subjects intended to discover or verify the clinical, pharmacological and/or other
pharmacodynamic effects of one or more investigation medicinal product(s), and/or identify any
adverse reactions to one or more investigation medicinal product(s), and/or to study absorption,
distribution, metabolism and excretion of one or more investigation medicinal product(s) with the
object of ascertaining its (their) safety and/or efficacy”.
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In Portugal, a clinical trial is submitted to three entities, which evaluate the proposal of a
clinical trial: CEIC, INFARMED and CNPD.
 CEIC – Comissão de Ética para a Investigação – Ethics Committee for Clinical
Research, an independent body consisting of healthcare professionals and non-
medical members whose responsibility is to protect the rights, safety and well-
being of human subjects in a trial at national level and to provide public assurance
of that protection, and which is in general responsible for issuing the ethic and
scientific single opinion; essential for conduction of clinical trials with medicinal
products for human use.
 INFARMED – Autoridade Nacional do Medicamento e Produtos de Saúde I.P. –
National Authority of Medicines and Health Products, Portuguese competent
authority.
 CNPD – Comissão Nacional de Protecção de Dados – National Data Protection
Authority.
The application to the CEIC may take place sequentially or in parallel with the application
to INFARMED and CNPD according to sponsor’s decision, considering that all information supplied
to Ethics Committee, CNPD and INFARMED are consistent. At the end of the CTA to the CEIC, it
must be assured that the information is updated according to the information submitted to
INFARMED (e.g. update of investigator brochure following the request for further information by
INFARMED), and if applicable to the CNPD. This is performed through a notification to the CEIC of
the new documents. A summary of the steps involved in CTA can be as follows:
o Step 1 – Submit the required documentation.
o Step 2 – Acknowledge the receipt of documents and validate the documentation.
(After validation, CEIC and INFARMED have a total of 60 days to give an opinion
while CNPD has no time limits).
o Step 3 – Evaluate the documentation.
o Step 4 – Ask questions, if necessary (At this stage, the time freezes).
o Step 5 – CRO / Sponsor answers the questions.
o Step 6 - CEIC, INFARMED acknowledge receipt of documents and validate
documentation (At this stage, time starts counting).
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o Step 7 – These entities evaluate the answers.
o Step 8 – Then, give their favorable opinion / authorization for clinical trial.
o Step 9 – After authorization of those three entities, clinical trials are submitted to
the Hospital’s Board of Directors in order to review, evaluate and sign the
financial contract. After being signed, it must then be sent to CEIC for evaluation
and it must be notified to INFARMED. After a positive assessment, the clinical trial
can be started in the research center.
In this clinical trial submission my tasks were to translate several documents, such as the
clinical trial agreement and the drug labels, to prepare a draft of the national coordinator ethics
agreement and to adapt the local informed consent form.
IDS Project II
In order to assure that the regulations and obligations of CTA sponsor investigators (SIs)
are met, Eurotrials’ R&D and Innovation department decided to create a CTA working package for
observational studies submission. The two most important goals of this CTA working package
offered to IDS sponsors are education of the research team about the regulatory process and
ongoing regulatory support to assure that the SIs’ obligations are met.
CTA for setting up an observational study are a little more simply than for clinical trials
with investigational products. The requests for authorization and opinion of the Local Ethics
Committee are addressed to the Institution Administration Board, to the Head of the Department
and to the Local Ethics Committee (CES) where the study will take place. If sensitive data are
collected, a request for authorization should be performed to CNPD in order to assure the
personal data confidentiality and security.
The CTA working package consists of templates of all the mandatory documents that need
to be prepared in a clinical trial application for setting up an observational study. These templates
come with guidance on how to efficiently complete them so that the process of CTA runs
smoothly and effortlessly.
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R&D and Innovation external training session.
In close collaboration with the pharmaceutical industry, medical societies, professional
associations, clinical research offices, Eurotrials has developed training programs designed to fit
the needs of the groups, fostering the sharing of knowledge and experiences.
Clinical Research is an area in constant change and the experience acquired in the
development of clinical trials and epidemiological studies as well as assimilated know-how in
translational medicine makes Eurotrials as an acknowledged partner in training courses.
My collaboration with the T&T department concerned the development and conduction
of an external training session entitled “Process of discovery of drugs and preclinical
requirements”, directed to the Medical Scientific Advisors of a Pharmaceutical Company (Slides
presentation in Attachment I). In this external session I was responsible for the “Non-clinical
Development” slides presentation.
This course sought to transmit the main concepts regarding the process of product
development by addressing activities related to the development cycle of medicines and
biologics, from its discovery to its commercialization. This training session occurred in December
2011 and the participants were requested to fill a form to evaluate the training session. Table 2
summarizes the results concerning my performance in this training session.
Table 2 – Global Evaluation of the training action. (Total number of respondents – 8)
Evaluated Item                                                                                                      (%)
Achieving the objectives of the action by the trainer
Very good 62,5
37,5Good
Clarity of presentation, n (%)
Very good 50
50Good
Technical expertise of the trainer, n (%)
Very good 75
25Good
Pedagogical competence of the trainer, n (%)
Very good 62,5
37,5Good
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Discussion and Conclusion
Developing and presenting a training report can be very challenging, since it is very
difficult to fully translate all the efforts made during this 9 months experience into it. In the next
few paragraphs some of the challenges and difficulties experienced in the conduct of various
activities will be presented.
It is not easy to work in an area that is outside of the core business of the company,
clinical trials, where there are standard operating procedures that enable an automation of
processes. In R&D and Innovation department every project is different from the previous one
and needs to be handled in a different way. Furthermore, this department demands a
multidisciplinary expertise covering areas such as preclinical and clinical development, regulatory
and business. Alongside with this, the current economic juncture of the country caused the
increasing difficulty in the implementation and development of projects in this area. However,
despite the current difficulties, I truly believe that this department may represent an important
driver for the company growth in the future through business development in Portugal but also in
the countries where Eurotrials operates, particularly Brazil.
In order to map the expression of interest by Pharmaceutical Companies in partnerships
with scientific institutions and the areas of potential collaboration in terms of therapeutic areas
and the purpose for these partnerships, I was asked to screen Pharmaceutical Companies’
websites on the subject of partnering. This research was very interesting and very fruitful because
it allowed me to study Pharmaceutical Companies’ main therapeutic areas interest and divide
them through these interests and also acknowledge their product pipeline. There were no big
challenges associated this task besides the fact that sometimes the desired information was in
some websites not easily accessed.  The challenge is to keep this information updated which
means regular visits to the Pharmaceutical Companies’ websites.
The same strategy was also applied to medical devices companies. The rationale for this
survey was different than the one regarding pharmaceutical companies’ interests. The main
purpose was to build a database of medical devices companies in order to establish a
communication network to present Eurotrials services. I can say without a doubt that this
research was the one where I learned the most mainly because this area is in constant
development and evolution. The number of medical devices available is overwhelming and most
of them with indications for which I was completely unaware.
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Additionally, startup companies operating in the healthcare sector were screened in the
context of potentially establishing a match between Pharmaceutical Companies’ interests and
these companies field of expertize. These surveys are of utmost importance to Eurotrials R&D and
Innovation department since they facilitate the tracking of a potential partner by allowing an easy
correlation between an academic institution research on a given therapeutic area and a
Pharmaceutical Company interested in establishing a partnership in the same therapeutic area.
Leveraging academic partnerships was probably the assignment that I found most
challenging and at the same time, the one that I enjoyed the most. The company already has a
proven track record in leveraging partnerships, such as the R&D platform, and its main objective is
to use these partnerships as successful case-studies to lure more partnerships underpinned by its
success.
Establishing academic partnerships is not as straightforward as one would suppose. In
fact, it is quite challenging. The first difficulty is to understand the research being made by the
investigator, sometimes in areas where we are not familiar with, in a short amount of time. In
order to achieve this, a lot of research and literature reading is necessary. After being acquainted
with the research it is necessary to evaluate its novelty and uniqueness compared to its
competitors and its potential application(s). The second difficulty is to make the investigators
understand the difference between product and technology and this is very important in order to
facilitate the search for a potential partner and/or in terms of technology transfer. Although this
may seem simple, the reality is that it is not given that for the same research project it possible to
have both a product and a technology.
This experience was very positive and the fact that the investigators were very interested,
motivated and eager to go forward with the projects made it all extremely interesting.
IDS are an important aspect of medical research and such studies are getting more and
more preponderance within Pharmaceutical Companies. These studies are extremely important
for Pharmaceutical Companies since most of these studies intend to demonstrate the efficacy of a
given drug on another indication besides the ones it has market authorization and on clinical
patient-oriented research that involves testing new discoveries in the clinic by carrying out
carefully controlled investigations on patients. The IDS enable the Pharmaceutical Companies to
maintain a trustworthy and close relation with key opinion leaders. This is also true for the CRO
because the key aspect of clinical trial monitorization is the communication especially with key
opinion leaders that usually are the clinical studies national coordinators.
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The obstacles associated with IDS are created by an increasing burden of bureaucracy.
Complying with all the regulatory procedures for a clinical trial application is one big problem in
these studies, particularly for academic researchers. While working in an IDS submission, I had the
opportunity to be involved in some of these procedures. In order to be aware of all procedures, I
have read all the documentation regarding the submission of clinical trials and I found it very
useful since I have now a broader perspective of clinical trials.
Finally, I learned very much while preparing the presentation for the Medical Scientific
Advisors of Pharmaceutical Company. Along with the knowledge gained through the literature
revision, I truly enjoyed this opportunity to connect with pharmaceutical industry professionals
and to exchange some ideas with them.
Overall, this 9-month was an extremely rich experience, in which I have learned very
much, participated in several projects ranging from basic research until clinical trials submission,
connected with several investigators from different backgrounds and I can say that I have now
several tools that will be very important in my future.
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Attachment I
“Process of discovery of drugs and preclinical requirements” Presentation - In this external
training session I was responsible for the “Non-clinical Development” slides presentation.
Process of discovery of drugs and preclinical requirements
Ana Filipa Bernardo e Ricardo Cunha – 21 Dezembro 2011
Process of discovery
of drugs and
preclinical
requirements
Process of discovery of drugs and preclinical requirements
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• I&D – o novo paradigma
• O desenvolvimento do medicamento
Programa - tópicos
Process of discovery of drugs and preclinical requirements
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Enquadramento do I&D biofarmacêutico
Cadeia de desenvolvimento do medicamento
Fonte: Pharmaceutical Industry profile 2005-phrma
Process of discovery of drugs and preclinical requirements
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O custo de desenvolvimento de um novo fármaco
tem aumentado significativamente
Enquadramento do I&D biofarmacêutico
Aumento do custo de desenvolvimento
Process of discovery of drugs and preclinical requirements
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Fonte:
EFPIA The Pharmaceutical
Industry in Figures 2010
Decréscimo no número de
novas entidades aprovadas
Enquadramento do I&D biofarmacêutico
Decrescimo de NME
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Enquadramento do I&D biofarmacêutico
As taxas de insucesso das fases clínicas aumentaram
Failure rates in clinical trials have increased.  Bain model 2003
Process of discovery of drugs and preclinical requirements
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O aumento do “Innovation Gap”: investimento em I&D
versus a aprovação de novos fármacos
Enquadramento do I&D biofarmacêutico
Innovation gap
Process of discovery of drugs and preclinical requirements
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I&D
Productividade
Process of discovery of drugs and preclinical requirements
Ana Filipa Bernardo e Ricardo Cunha – 21 Dezembro 2011
I&D
Productividade
Process of discovery of drugs and preclinical requirements
Ana Filipa Bernardo e Ricardo Cunha – 21 Dezembro 2011
I&D
O paradigma tradicional não satisfazia as necessidades
• Innovation Gap - Investimento aumenta,  nº de
medicamentos decresce
• 2006: Apenas 25 novos medicamentos a nível
mundial, dos quais 7 são produtos biológicos
Source: The Pharmaceutical Industry in Figures EFPIA Edition 2008
• Custo de um novo medicamento atinge 1.3 mil
milhões de dólares, em 2006
Source: J.A. DiMasi and H.G. Grabowski “The Cost of Biopharmaceutical R&D: Is
Biotech Different?” Managerail and Decision Economics 28 (2007):469-479
Process of discovery of drugs and preclinical requirements
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I&D
O paradigma tradicional não satisfazia as necessidades
• Crescentes preocupações de segurança durante o I&D
• A eficácia e a segurança são os principais factores de
constrição no I&D.
Source: Kola I and Landis J (2004). A Survey of Pharmaceutical Companies Comparing
Reasons for Attrition. Nature Reviews Drug Discovery; 3: 711–715.
• Novas exigências de farmacovigilância e gestão de risco.
• Vários fármacos são descontinuados após comercialização,
devido a problemas de segurança.
• Impacto económico das decisões das agências reguladoras
Process of discovery of drugs and preclinical requirements
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I&D
O paradigma tradicional não satisfazia as necessidades
• Com as novas tecnologias de informação temos doentes mais
informados
• Cerca de  30% dos doentes não beneficia dos medicamentos
Source: JAMA 1998, 279, 1200
• Estima-se que 197.000 morte por ano sejam devidas a
reacções adversas com um custo total para a sociedade de
na EU de € 79billion.
• Estima-se que 5% das hospitalizações são devidas a reacções
adversas a medicamentos.
• Na Europa, estima-se que o custo associado  às  doenças
crónicas ascenda a 70% dos custos totais em saúde.
Source: eHealth Taskforce report 2007 European Commission
• Necessidade de novas soluções terapêuticas custo-efectivas
Process of discovery of drugs and preclinical requirements
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Expansão das capacidades
Conhecimento e a Tecnologia
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Enquadramento do I&D biofarmacêutico
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Enquadramento do I&D biofarmacêutico
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Alteração do paradigma
de I&D biofarmacêutico
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 I&D transponível para a sociedade
I&D
I&D transponível para a sociedade
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Pressão a nível
dos cuidados
de saúde:
Benefício-risco
Pressões
económicas:
Benefício-custo
Rentabilização
do investimento
em I&D
Necessidade de soluções terapêuticas diferenciadoras que
impactem positivamente a saúde pública
InovaçãoMedicina personalizada
 Medicina personalizada
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 The US National Cancer Institute defines personalisedmedicine as: “the use of
information about a person’s genes, proteins, and environment to prevent,
diagnose, and treat disease.”
US National Cancer Institute
 Personalisedmedicine may be defined as “a medical model using molecular
profiling technologies for tailoring the right therapeutic strategy for the right
person at the right time, and determine the predisposition to disease at the
population level and to deliver timely and stratified prevention”.
European Commission, DG Research - Brussels,  10-11 June 2010
 Medicina personalizada
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 Medicina personalizada
D. Foernzler, 3rd Biomarker Congress, Manchester, 14-15 May 2008
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Pathway for the development of tuberculosis diagnostics, from needs assessment to
delivery [reproduced from reference from the World Health Organization].
World Health Organization Stop TB Partnership New Diagnostics Working Group. Pathways to better
diagnostics for tuberculosis: a blueprint for the development of TB diagnostics. Geneva,
Switzerland: WHO, 2009. http://whqlibdoc.who.int/ publications/2009/9789241598811_eng.pdf
Accessed September 2010.
Cadeia de I&D
 Avaliação da inovação
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Layer 1: Effectiveness analysis
How well does the new tool work in terms of accuracy?
How many additional cases will be identified who would otherwise not have been identified?
How many additional cases will actually start (and complete) treatment as a result of using the
new tool?
Layer 2: Equity analysis
Who benefits from the new tool (ambulant vs. hospitalised, poor/less poor, men/women,
adults/children)?
Why do these benefits accrue (level health system in which new diagnostic is deployed, change
in time to issue of results, change in patient costs)?
 Avaliação da inovação
Process of discovery of drugs and preclinical requirements
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Layer 4: Scale-up analysis
What are the projected impacts of going to scale with the new tool?
1 Cost savings to patients in relation to income
2 Cost savings to health providers/the health system
3 Effects on transmission of improved infection control as a result of the new tool
Layer 5: Policy analysis
What other similar technologies are available or likely to become available?
How do similar existing or emerging technologies compare in their projected performance
within each of the layers above?
Layer 3: Health systems analysis
What are the human resource implications of introducing the new tool (training, number and
cadre of staff)?
What are the infrastructure implications (equipment, laboratory layout, safety installations)?
What are the procurement implications (reagents, consumables, documentation)?
What are the implications for quality assurance (internal and external)?
 Avaliação da inovação
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Pathway for the development of tuberculosis diagnostics, from needs assessment to
delivery [reproduced from reference from the World Health Organization].
World Health Organization Stop TB Partnership New Diagnostics Working Group. Pathways to better
diagnostics for tuberculosis: a blueprint for the development of TB diagnostics. Geneva,
Switzerland: WHO, 2009. http://whqlibdoc.who.int/ publications/2009/9789241598811_eng.pdf
Accessed September 2010.
Cadeia de I&D
 Avaliação da inovação
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“in our experience, the traditional functional Product LifeCycle Management organization
of a Life Sciences company suffers from virtual walls between the functional silos, product
and process data being separated making it difficult for cross-functional information to
flow quiclky and securely”
 Product Lifecycle Management
Fonte: Product Life Cycle Management in Life Sciences Industry- 2010 Deloitte Consulting AG.
Process of discovery of drugs and preclinical requirements
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Um período de mudanças sem precedentes.:
 As alterações demográficas da população,
 Conhecimento da doença,
 A entrada de novas tecnologias,
 Aumento das regulamentações
 O conhecimento e as exigências do doente
 Os custos de saúde
 Product Lifecycle Management
As empresas terão de mudar radicalmente a fim de lidar com o
futuro ambiente da indústria
Process of discovery of drugs and preclinical requirements
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Fonte: Product Life Cycle Management in Life Sciences Industry- 2010 Deloitte Consulting AG.
 Product Lifecycle Management
Uma abordagem integradora que gere o produto e o conhecimento
Process of discovery of drugs and preclinical requirements
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Fonte: Product Life Cycle Management in Life Sciences Industry- 2010 Deloitte Consulting AG.
 Product Lifecycle Management
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 Target Product Profile
Target Product Profile (TPP) é um resumo do programa de desenvolvimento do
medicamento descrito em termos de conceitos rotulagem
• É preparado por todos os departamentos da empresa envolvidos no
desenvolvimento da terapêutica ou de diagnóstico
• O TPP é um "documento vivo" evoluindo e amadurecendo com o crescente
conhecimento e experiência
• A sua apresentação à FDA é voluntária, mas tem benefícios específicos
Process of discovery of drugs and preclinical requirements
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 Target Product Profile
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 Target Product Profile
O TPP têm um papel crescente na indústria farmacêutica, designadamente na
Gestão Estratégica de um Programa
O TPP explora vários cenários rotulagem: Alvo, Mínimo, Óptimo
O TPP estima para cada cenário
• as probabilidades de sucesso
• Custos de Desenvolvimento
• Pessoal
• Manufactura
• Penetração de mercado / concorrentes
Process of discovery of drugs and preclinical requirements
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 Target Product Profile
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 Target Product Profile
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 Target Product Profile (exemplo)
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I. Statement of purpose
This document has been prepared for the Advance Market Commitment (AMC) for pneumococcal
vaccines. The AMC is a financial commitment to subsidize the future purchase, up to a pre-agreed
price for a vaccine not yet available, if it is requested by a GAVI-eligible country. The pneumococcal
vaccine has been selected to pilot this new financing instrument. As part of the AMC process,
specifications for eligible products need to be defined in advance. These product specifications are
called the target product profile (TPP). In accordance with the relevant AMC legal documents, the
characteristics are set at the beginning of the AMC process and can subsequently only be modified by
the independent assessment committee (IAC) to render the product requirements less stringent. The
TPP defines essential criteria that relate to the public health impact and suitability of the product,
covering measures of vaccine efficacy, safety, dose-scheduling, presentation and packaging. The
suitability for use in GAVI-eligible countries is the overall guiding principle. At the same time the
criteria should help to stimulate a competitive vaccine supply environment, by providing incentives to
a large number of vaccine developers. Therefore, essential vaccine attributes need to be demanding,
yet realistic, in relation to the innovation that can be achieved over the duration of the
pneumococcal AMC. All attributes must be unequivocal and measurable by vaccine developers.
 Target Product Profile (exemplo)
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 Target Product Profile (exemplo)
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 Open innovation
Fonte: Product Life Cycle Management in Life Sciences Industry- 2010 Deloitte Consulting AG.
Hospitals
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 Open innovation
Burrill & Company
Process of discovery of drugs and preclinical requirements
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 Investigação colaborativa
Num processo de Investigação colaborativa - open innovation;
LICENCIAMENTO & AQUISIÇÕES
INOVAÇÃO EXTERNA
Academia Bioetch Farma Consórcios
INVESTIGAÇÃO INTERNA
Discovery Early Development
Late Development New Drug Application
Process of discovery of drugs and preclinical requirements
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 Investigação colaborativa
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Investigação de Translação
Processo de grande interacção entre academia, os hospitais e as empresas.
Um plano de estudo optimizado, com um foco no mercado (nas necessidades
clínicas) e na viabilidade do processo com pontos de decisão de go/no-go.
 Investigação colaborativa
Process of discovery of drugs and preclinical requirements
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Dados Clínicos
Genética de populações
Biobancos
Farmacovigilância
Medicamentos e dispositivos
médicos
Epidemiologia
Imagiologia
Proteínas
Genómica
Saúde Pública
Bioinformatica
Patofisiologia
Farmacologia
Estudos Comportamentais
Multidisciplinar
Integração do conhecimento multidisciplinar
 Investigação colaborativa
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Agregação do conhecimento
e foco no doente
Bioinformatics
Information Technology
Metabolomics
Genomics
Proteomics
Imagiology
Clinical data
Laboratory data
Disease Physiopathology Public Health
PharmacovigilanceR&D drugs and devicesPharmacology      Toxicology
Discovery Leadoptimizatin Preclinical Clinical
 Investigação colaborativa
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Academia Hospitais
Empresas
Academia
Industria
Hospitais
Agregação do conhecimento e foco no doente
 Investigação colaborativa
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 Investigação colaborativa
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 Investigação colaborativa - Plataformas de I&D
Create Health - A Strategic Centre for Translational Cancer
Research
CREATE Health is a Strategic Centre for Translational Cancer
research located in the Biomedical Centre in Lund. The Centre
is funded by the Swedish Foundation for Strategic Research. By
integrating clinicians and researchers from Lund University
Hospital with researchers from the Faculties of Medicine, Natural
Sciences and Engineering using a superbly equipped and
integrated “omics” platform, concentrated in a single area, a
centre unique in its kind has been created.
The vision of CREATE Health is to use an integrative approach
to develop novel diagnostics and therapeutics, based on identified
markers and molecular signatures and to create a substantial
social impact for the patient, through direct application of research
for selection of an optimal, individually-based, cancer treatment.
Process of discovery of drugs and preclinical requirements
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 Investigação colaborativa - Plataformas de I&D
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 Cadeia de desenvolvimento do medicamento
Registo do
medicamento
Fase Pré-clínica Fase I Fase II Fase III Fase IV
Tempo
Process of discovery of drugs and preclinical requirements
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Registo do
medicamento
Fase Pré-clínica Fase I Fase II Fase III Fase IV
Testes animais - avaliar segurança
- Testes Farmacológicos
- Teste Toxicológicos
- Testes específicos (reprodução, carcinogénese, mutagénese)
“ Os candidatos” a fármacos
Tempo
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Fase Pré-clínica Fase I Fase II Fase III Fase IV
n= 20-100
População = Voluntários saudáveis
Objectivos:
Avaliação da Segurança e Tolerabilidade Inicial
- Farmacocinética
- Farmacodinâmica
Fase I
Tempo
Registo do
medicamento
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Fase Pré-clínica Fase I
Farmacodinâmica
é a área da farmacologia que estuda os efeitos fisiológicos dos fármacos nos
organismos, seus mecanismos de acção e a relação entre concentração do fármaco
e efeito. De forma simplificada, podemos considerar farmacodinâmica como o
estudo do efeito do medicamento no organismo/ tecidos.
Farmacocinética
é o caminho que o medicamento faz no organismo. Não se trata do estudo do seu
mecanismo de acção, mas sim as etapas que o medicamento sofre desde a
administração até a excreção, que são: absorção, distribuição, bio-
transformação e excreção.
Fase I
Tempo
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Fase Pré-clínica Fase I Fase II Fase III Fase IV
n=100-500
População: Doentes muito seleccionados
(patologia única)
Objectivo: explorar eficácia e avaliar segurança
Variáveis em estudo: Várias (ex: Curva de
dose-resposta, regimes terapêuticos, End-
points potenciais)
Fase II
Tempo
Registo do
medicamento
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Fase Pré-clínica Fase I Fase II Fase III Fase IV
n= 1000-5000
Objectivo principal: demonstrar ou confirmar
beneficio terapêutico
Objectivo secundário: testar eficácia e segurança
População: Doentes menos seleccionados
(patologias associados se ligeiras);
Variáveis em estudo: comparação com terapias
existentes; cumprir as regulamentações
Tempo
Fase III
Registo do
medicamento
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Fase Pré-clínica Fase I Fase II Fase III Fase IV
Objectivo principal: optimizar o uso do medicamento
Variáveis em estudo: diferentes formulações, dosagens,
durações de tratamento, interacções medicamentosas,
comparações com outros fármacos, diferentes escalões etários,
farmacovigilância, etc.
Tempo
Fase IV
Registo do
medicamento
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ICH Topic E8 – General Considerations for Clinical Trials – 3.1.3
FASE I
FASE II
FASE III
FASE IV
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ICH Topic E8 – General Considerations for Clinical Trials – 3.1.3
Fases dos Ensaios Clínicos vs Tipos de Estudos
I            II             III           IV
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Patient-Oriented
Research
+ omics
+ tecnologias
Um novo processo
de desenvolvimento
 Cadeia de desenvolvimento do medicamento
Process of discovery of drugs and preclinical requirements
Ana Filipa Bernardo e Ricardo Cunha – 21 Dezembro 2011
Novas abordagens de Investigação Clínica
Outros estudos clínicos terapêuticos (ex. combinação diagnóstico, terapêutica)
Estudos Clínicos com dispositivos médicos
(ex. diagnósticos com biomarcadores das “omicas”, softwares de
monitorização, preditivos…)
Outros estudos “patient-oriented” interventivos e não interventivos
(ex. fisiopatologia, biobancos, farmacogenómica, estratificação de doentes)
 Cadeia de desenvolvimento do medicamento
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Estudos de caracterização da doença
Estudos de estratificação dos doentes
Estudos de confirmação in vivo de evidências in vitro
Estudos de caracterização de biomarcadores
(preditivos, diagnóstico, prognóstico da doença)
Estudos de validação de biomarcadores
Estudos farmacogenéticos
Estudos de economia da saúde
Epidemiologia
Genómica
Metabolómica
Proteonómica
Estudos clínicos
Bioinformática
Biologia de
Sistemas
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Um novo
processo de
desenvolvimento
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Um novo processo de desenvolvimento - In-life testing &
Live License
Fonte: New Trends and Paradigm sin CR&D Focus on Critical Path Initiative
ClinicalTrials and Business Process Optimisation NNIT Life Sciences Conference, Kopenhagen, DNOct3, 2007
Yves Geysels, PhD , Head Clinical Research Operations, Belgium Novartis
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Post-authorisation safety studies (PASS)  PAES
Estudos farmacoepidemiologicos ou ensaios clínicos realizados de acordo
com o AIM e com o objectivo de identificar ou quantificar  reacções adversas
ao produto medicinal (Artigo 1 (15) Directiva 2001/83/EC)
Estudos não-interventivos e interventivos (phase IV)
In-life testing & Live License – estudos clínicos
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Outros estudos clínicos… Iniciativa do Investigador
Estudos de validação de guidelines
Estudos em populações sub-representadas como as crianças, os idosos e em
doenças raras ou doenças pouco estudadas.
Estudos ‘multi-modal’ para estudar a combinação de vários fármacos ou de
fármacos com cirurgia
Estudos para identificar subpopulações de doentes (respondedores/ não-
respondedores)
Estudos para identificar endpoints clínicos relevantes para a pratica clínica e
necessidades dos doentes.
Meta-analises utilizando dados individualizados de doentes
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Exploratory clinical trials
POC
Adaptative trials (Adaptative, Seamless and Adaptive Seamless Designs)
Outros….
Desenvolvimento da molécula – estudos clínicos
Desenhos flexíveis, data-led e desenvolvimento de estudos em simultâneo
 Cadeia de desenvolvimento do medicamento
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“Exploratory clinical trials play a crucial role in identifying the drugs that are likely to
fail, therefore enabling a faster go/no-go decision that can save vital time and
resources”
Human microdosing studies/ Phase 0 clinical trialsoffer the promise of improved candidate selection,
reduced attrition rates, safer clinical studies and a potential reduction in the use of animals in early clinical
development), developed in response to the United States Food and Drug Administration (FDA)'s recent
exploratory Investigational New Drug (IND) guidance, are intended to expedite the clinical evaluation of new
molecular entities. The exploratory IND supports the performance of first-in-human testing of new
investigational agents at subtherapeutic doses based on reduced manufacturing and toxicologic
requirements, allowing the demonstration of drug-target effects and assessment of pharmacokinetic-
pharmacodynamic relationships in humans earlier in clinical development. The objectives of a phase 0
cancer clinical trial are to establish at the very earliest opportunity-before large numbers of patients have
been accrued and exposed to potential drug-associated toxicity-whether an agent is modulating its target in a
tumor, and consequently whether further clinical development is warranted. We review here the fundamental
requirements of clinical studies conducted under an exploratory IND and address some common
misconceptions regarding oncologic phase 0 trials. Source: Cancer J. 2008 May-Jun;14(3):133-7.
Phase 0 clinical trials: conceptions and misconceptions.
Exploratory clinical trials
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“The construction of working prototypes of the necessary functionality and
infrastructure in sufficient quality to investigate evidence for improving health in daily
use for a suitable period of time; a limited but relevant set of people serving as
subjects.”
Source:
Pervasive Healthcare as a Scientific Discipline J. E.
BardramIT University of Copenhagen, Copenhagen,
Denmark
POC – Proof of Concept
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Source: New Trends and Paradigm sin CR&D Focus on Critical Path Initiative
ClinicalTrials and Business Process Optimisation NNIT Life Sciences Conference, Kopenhagen, DNOct3, 2007
Yves Geysels, PhD , Head Clinical Research Operations, Belgium Novartis
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 Cadeia de desenvolvimento do medicamento
ASD Trial -
Example
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Desenvolvimento não clínico
Conceitos de farmacocinética e farmacodinâmica
Programa - tópicos
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Desenvolvimento pré-clinico
Selectividade – In order to pursue chemotherapy successfully we
must look for substances which possess a high affinity and high
lethal potency in relation to the parasites, but have a low toxicity
in relation to the body, so that it becomes possible to kill the
parasites without damaging the body to any great extent. We want
to hit the parasites as selectively as possible. In other words, we
must learn to aim and to aim in a chemical sense.”
(Paul Ehrlich);
Dose – “All substances are poisonous, there is none that is not a
poison; the right dose differentiates a poison from a remedy. ”
(Paracelsus)
Process of discovery of drugs and preclinical requirements
Ana Filipa Bernardo e Ricardo Cunha – 21 Dezembro 2011
So, you have an interesting drug/molecule/antibody/vaccine etc…
You have conducted experiments showing some activity in vitro or even better
in vivo…
Does your nonclinical model system (in vitro? In vivo?) approximate a clinical
situation? – Relevance!
Do you have Proof of Concept?...Does my product do what it’s expected to
do?
Or, do you have a drug in search of an indication?
Kunder S. & Pepperl DJ. 2009
Desenvolvimento pré-clinico
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Work through development from the goal
BACKWARDS:
Start with desired label
Determine pivotal trials for the label Phase III
Determine the preliminary trials needed for pivotal trials – Phase I, II
Determine the preclinical data needed to conduct
Clinical trials … usually focus on Phase 1 initially
Kunder S. & Pepperl DJ. 2009
Desenvolvimento pré-clinico
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O que é que a fase de desenvolvimento não
clinico necessita de saber dos objectivos clínicos?
–  A indicação
–  Duração do tratamento
–  Tempos clínicos
–  Experiência prévia com produtos/classe similares
Desenvolvimento pré-clinico
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A indicação?
–  Doença grave ou de menor severidade?
• No caso de estarmos a testar um fármaco para uma doença grave podemos
beneficiar de um desenvolvimento mais rápido e de uma maior tolerância a
nível regulamentar relativamente a potênciais toxicidades.
–  Existe alguma terapia aprovada ou é o primeiro fármaco?
• No caso de estarmos perante uma doença que ainda não tem uma terapia
aprovada podemos beneficiar de um desenvolvimento mais rápido, o mesmo
acontecendo no caso de um medicamento que apresente evidentes melhorias
relativamente a um fármaco já existente para uma dada condição.
Desenvolvimento pré-clinico
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Dados que suportem a CMC
– Desenvolvimento quimico e farmaceutico – sintese,
purificação, estabilidade e desenvolvimento de formulação
adequada
–  Deve haver uma caracterização qualitativa das impurezas
Desenvolvimento pré-clinico
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–  Permite a determinação da quantidade de fármaco necessário para o
desenvolvimento clínico e da via de administração e posologia
–  Alocação dos recursos
–  Programação dos estudos
–  Coordenação com as CROs
–  Estabelecimento de prazos e metas
–  Serve de base para um processo de submissão
Desenvolvimento pré-clinico
Integração do CMC com o desenvolvimento Clinico e Pré-clinico
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The nonclinical safety assessment for marketing approval of a pharmaceutical usually includes
pharmacology studies, general toxicity studies, toxicokinetic and nonclinical pharmacokinetic
studies, reproduction toxicity studies, genotoxicity studies and, for drugs that have special
cause for concern or are intended for a long duration of use, an assessment of carcinogenic
potential. Other nonclinical studies to assess phototoxicity, immunotoxicity, juvenile animal
toxicity and abuse liability should be conducted on a case-by-case basis.
Desenvolvimento pré-clinico
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http://www.eurofins.com/pharma-services/pharma-services/pharma-early-development.aspx
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Primary pharmacology / Pharmacodynamic
–  Studies on the mode of action and/or effects of a substance in relation to its desired
therepeutic target are primary pharmacodynamic studies.
Secondary Pharmacology / Pharmacodynamic
–  Studies on the mode of action and/or effects of a substance not related to its desired
therapeutic target.
Valentin JP. J Pharmacol Tox Methods, 2008
Desenvolvimento pré-clinico
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Pharmacokinetics
Desenvolvimento pré-clinico
• Identification of metabolites (since these may be
the active form of the compound)
• Evidence of bioavailability (to assist in design of
clinical trials and assess toxicity)
• Establishment of principal route of administration
and rate of elimination
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Why are Pharmacology Studies Important?
• Establish basis for conducting trial
– interaction with target receptor, tissue, or organ
– degree of pharmacodynamic (P/D) effect
– correlation of P/D effect with exposure
• Optimize dosing, regimen for the clinic
• Optimize route of administration
• Selection of species for further testing
Desenvolvimento pré-clinico
Process of discovery of drugs and preclinical requirements
Ana Filipa Bernardo e Ricardo Cunha – 21 Dezembro 2011
Why are Pharmacokinetic Studies Important?
• Demonstration of the pharmacokinetics of a new biologic allows estimation of:
– exposure to agent after any given dose
– correlation with pharmacologic/therapeutic effect
– duration of exposure (half-life)
– dosing interval for the clinical study
– time to reversal of any biologic or toxic effects
– development of anti-product antibodies
– both total and neutralizing activity
Desenvolvimento pré-clinico
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Why is Toxicology Testing for Any New Biologic
Important?
• Provides information regarding the safety of single and/or repeated exposure to
the biologic anti-cancer agent
– toxicities related to the dose of product given
– toxicities related to the duration of product administration
– identification of target organs
– reversibility of toxicities
– after clearance of the biologic product
– after development of neutralizing antibodies
Desenvolvimento pré-clinico
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What Do I Need to Measure in Toxicology Testing?
• Pharmacokinetics/toxicokinetics
– correlation of serum levels of biologic with toxicity, pharmacodynamic activity
– identification of elimination half-life and antibody development (reversibility)
• Pathology
– gross and microscopic evaluation of tissue damage
– most sensitive indicator, but final!
– confirmation of target organ toxicity detected biochemically
Desenvolvimento pré-clinico
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What Else Do I Need to Include in My Toxicology Studies?
• Administration/dose selection
– route & dosing regimen should mimic proposed clinical use
– alternative routes/regimens acceptable in some cases
– attainment of toxic dose, no observable adverse effect level (NOAEL) desirable
– multiples of human dose needed to determine adequate safety margins
– can vary with product class and/or clinical indication
Desenvolvimento pré-clinico
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Other Toxicology Studies
• Local tolerance studies
– If warranted by route of administration
• Genotoxicity studies
• Reproductive Toxicity studies
• Carcinogenicity studies
Desenvolvimento pré-clinico
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How Are Toxicology Studies Used to Support a New IND?
• Nonclinical toxicology data are used to make recommendations regarding the conduct
of the clinical trial, based on the safety data obtained
– initial safe starting dose, dose-escalation scheme
– target organ(s), reversibility of toxicity
– appropriate parameters for clinical monitoring
– identify “at risk” patient populations (inclusion/exclusion criteria)
Desenvolvimento pré-clinico
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Goals of Non-Clinical Testing of Small Molecule Drugs
• To characterize potential adverse drug effects
– Define end organ toxicities
– Define reversibility of toxicity
• To characterize pharmacokinetic profile
• To characterize beneficial pharmacodynamic effects
– Proof of principle
• To guide safe use in human clinical studies
– To determine a safe & reasonable starting dose
– Provide monitoring guidelines for the clinical study
• Provide sufficient data to conclude that patients are not exposed to
unreasonable risks - Potential for benefit must also exist
Desenvolvimento pré-clinico
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Problems with animal models
• Mice are not men
• Transplanted human tumors behave very differently
• Uniformity of models: important for reproducibility, but
inherently different from natural system
Desenvolvimento pré-clinico
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Ideal Animal Model
• Validity
• Selectivity
• Predictability
• Reproducibility
“There is no perfect tumor model”
Desenvolvimento pré-clinico
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– The nonclinical development plan is customized for a particular product and
indication
– Regulatory guidances are a starting point for assembling your product’s
development plan
– The nonclinical plan integrates with the clinical development plan
– The nonclinical plan, its studies and the study results need to support the
case‐by‐case risk/benefit assessment by the regulatory reviewers (nonclinical
and clinical)
Conclusions
Kunder S. & Pepperl DJ. 2009
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Ensaios clínicos – First in Man
Programa - tópicos
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Ensaios clínicos – First in Man
Os primeiros estudos no Humano (FIH) fazem parte da fase exploratória do
desenvolvimento de medicamentos e representam um marco significativo no
desenvolvimento clínico de novos medicamentos.
Nesta fase estão apenas disponíveis dados pré-clínicos para orientar a selecção de
dose, da população, desenho do estudo e monitorização de segurança. Esta
informação é crítica para maximizar a segurança dos sujeitos do estudo e da qualidade
dos dados.
Adpatado – modulo 4
Clinical Pharmacology – Training Programe in Ppharmaceutical Medicine
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Ensaios clínicos – Phase I
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Ensaios clínicos – Phase I
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Ensaios clínicos – First in Man
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Ensaios clínicos – Phase I
Fonte: Chapter 6. Phase I Studies (Human Pharmacology) Edward M. Sellers, M.D., Ph.D.
Patrick du Souich, M.D., Ph.D.
Ventana Clinical Research Corporation and Departments of Pharmacology, Medicine and Psychiatry
University of Toronto Toronto, Ontario
EXPERIMENTAL DESIGN
Phase I studies usually have non-therapeutic objectives and as such are conducted in
healthy volunteer subjects. The studies may be open, baseline controlled or may use
randomisation and blinding. The design depends upon the aim of the study. When the
objective is to determine the tolerability of the dose range expected to be used in later
clinical studies and to assess the nature of adverse reactions, the study will typically
include both single and multiple dose administration and a placebo arm. The protocol
should specify the toxicity-based discontinuation of the study, as well as the dose
adjustment rules in presence of toxicity (2).
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Ensaios clínicos – Phase I
The MRSD for the first human clinical trial is derived from the no-observed
adverse effect levels (NOAELs) in the most appropriate species, conversion of
NOAELs to human equivalent doses (HED), and application of a safety factor.
DETERMINATION OF THE MAXIMUM RECOMMENDED STARTING DOSE (MRSD)
Fonte: Chapter 6. Phase I Studies (Human Pharmacology) Edward M. Sellers, M.D., Ph.D.
Patrick du Souich, M.D., Ph.D.
Ventana Clinical Research Corporation and Departments of Pharmacology, Medicine and Psychiatry
University of Toronto Toronto, Ontario
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I&D biofarmacêutico
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